Literature DB >> 22341523

Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells.

Dan Su1, Xiaoying Fu2, Songqing Fan3, Xiao Wu1, Xin-Xin Wang4, Liya Fu1, Xue-Yuan Dong2, Jianping Jenny Ni2, Li Fu5, Zhengmao Zhu6, Jin-Tang Dong7.   

Abstract

Whereas estrogen-estrogen receptor α (ER) signaling plays an important role in breast cancer growth, it is also necessary for the differentiation of normal breast epithelial cells. How this functional conversion occurs, however, remains unknown. Based on a genome-wide sequencing study that identified mutations in several breast cancer genes, we examined some of the genes for mutations, expression levels, and functional effects on cell proliferation and tumorigenesis. We present the data for C1orf64 or ER-related factor (ERRF) from 31 cell lines and 367 primary breast cancer tumors. Whereas mutation of ERRF was infrequent (1 of 79 or 1.3%), its expression was up-regulated in breast cancer, and the up-regulation was more common in lower-stage tumors. In addition, increased ERRF expression was significantly associated with ER and/or progesterone receptor (PR) positivity, which was still valid in human epidermal growth factor receptor 2 (HER2)-negative tumors. In ER-positive tumors, ERRF expression was inversely correlated with HER2 status. Furthermore, higher ERRF protein expression was significantly associated with better disease-free survival and overall survival, particularly in ER- and/or PR-positive and HER2-negative tumors (luminal A subtype). Functionally, knockdown of ERRF in two ER-positive breast cancer cell lines, T-47D and MDA-MB-361, suppressed cell growth in vitro and tumorigenesis in xenograft models. These results suggest that ERRF plays a role in estrogen-ER-mediated growth of breast cancer cells and could, thus, be a potential therapeutic target. Copyright Â
© 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341523      PMCID: PMC3349889          DOI: 10.1016/j.ajpath.2011.11.025

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Coregulator expression and breast cancer: improving the predictive power of estrogen receptor alpha.

Authors:  Erika Krasnickas Keeton; Myles Brown
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

Review 2.  Estrogen carcinogenesis in breast cancer.

Authors:  James D Yager; Nancy E Davidson
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

3.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.

Authors:  Robert L Strausberg; Elise A Feingold; Lynette H Grouse; Jeffery G Derge; Richard D Klausner; Francis S Collins; Lukas Wagner; Carolyn M Shenmen; Gregory D Schuler; Stephen F Altschul; Barry Zeeberg; Kenneth H Buetow; Carl F Schaefer; Narayan K Bhat; Ralph F Hopkins; Heather Jordan; Troy Moore; Steve I Max; Jun Wang; Florence Hsieh; Luda Diatchenko; Kate Marusina; Andrew A Farmer; Gerald M Rubin; Ling Hong; Mark Stapleton; M Bento Soares; Maria F Bonaldo; Tom L Casavant; Todd E Scheetz; Michael J Brownstein; Ted B Usdin; Shiraki Toshiyuki; Piero Carninci; Christa Prange; Sam S Raha; Naomi A Loquellano; Garrick J Peters; Rick D Abramson; Sara J Mullahy; Stephanie A Bosak; Paul J McEwan; Kevin J McKernan; Joel A Malek; Preethi H Gunaratne; Stephen Richards; Kim C Worley; Sarah Hale; Angela M Garcia; Laura J Gay; Stephen W Hulyk; Debbie K Villalon; Donna M Muzny; Erica J Sodergren; Xiuhua Lu; Richard A Gibbs; Jessica Fahey; Erin Helton; Mark Ketteman; Anuradha Madan; Stephanie Rodrigues; Amy Sanchez; Michelle Whiting; Anup Madan; Alice C Young; Yuriy Shevchenko; Gerard G Bouffard; Robert W Blakesley; Jeffrey W Touchman; Eric D Green; Mark C Dickson; Alex C Rodriguez; Jane Grimwood; Jeremy Schmutz; Richard M Myers; Yaron S N Butterfield; Martin I Krzywinski; Ursula Skalska; Duane E Smailus; Angelique Schnerch; Jacqueline E Schein; Steven J M Jones; Marco A Marra
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

4.  Characterization of chromosome 1 abnormalities in malignant melanomas.

Authors:  D Smedley; S Sidhar; S Birdsall; D Bennett; M Herlyn; C Cooper; J Shipley
Journal:  Genes Chromosomes Cancer       Date:  2000-05       Impact factor: 5.006

5.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

6.  HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy.

Authors:  Laura C Collins; Stuart J Schnitt
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

7.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.

Authors:  Xue-Yuan Dong; Carmen Rodriguez; Peng Guo; Xiaodong Sun; Jeffrey T Talbot; Wei Zhou; John Petros; Qunna Li; Robert L Vessella; Adam S Kibel; Victoria L Stevens; Eugenia E Calle; Jin-Tang Dong
Journal:  Hum Mol Genet       Date:  2008-01-17       Impact factor: 6.150

8.  Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.

Authors:  A F Gazdar; V Kurvari; A Virmani; L Gollahon; M Sakaguchi; M Westerfield; D Kodagoda; V Stasny; H T Cunningham; I I Wistuba; G Tomlinson; V Tonk; R Ashfaq; A M Leitch; J D Minna; J W Shay
Journal:  Int J Cancer       Date:  1998-12-09       Impact factor: 7.396

9.  Implication of snoRNA U50 in human breast cancer.

Authors:  Xue-Yuan Dong; Peng Guo; Jeff Boyd; Xiaodong Sun; Qunna Li; Wei Zhou; Jin-Tang Dong
Journal:  J Genet Genomics       Date:  2009-08       Impact factor: 4.275

Review 10.  Endocrine-responsive breast cancer and strategies for combating resistance.

Authors:  Simak Ali; R Charles Coombes
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

View more
  9 in total

1.  Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.

Authors:  Sakineh Abbasi; Mina Rasouli; Mehrnaz Nouri; Samira Kalbasi
Journal:  Int J Clin Exp Med       Date:  2012-11-18

2.  Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.

Authors:  Ali Naderi
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-24

3.  C1orf64 is a novel androgen receptor target gene and coregulator that interacts with 14-3-3 protein in breast cancer.

Authors:  Ali Naderi
Journal:  Oncotarget       Date:  2017-05-11

4.  ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.

Authors:  Leilei Qi; Baotong Zhang; Shiying Zhang; Xinpei Ci; Qiao Wu; Gui Ma; Ang Luo; Liya Fu; Jamie L King; Rita Nahta; Jin-Tang Dong
Journal:  Oncotarget       Date:  2017-05-30

5.  SRARP and HSPB7 are epigenetically regulated gene pairs that function as tumor suppressors and predict clinical outcome in malignancies.

Authors:  Ali Naderi
Journal:  Mol Oncol       Date:  2018-04-16       Impact factor: 6.603

6.  CAncer bioMarker Prediction Pipeline (CAMPP)-A standardized framework for the analysis of quantitative biological data.

Authors:  Thilde Terkelsen; Anders Krogh; Elena Papaleo
Journal:  PLoS Comput Biol       Date:  2020-03-16       Impact factor: 4.475

7.  PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.

Authors:  Yong Bao; Christopher Qian; Meng-Yue Liu; Fei Jiang; Xiaoxiao Jiang; Huijuan Liu; Zhuqing Zhang; Fanghui Sun; Ningwei Fu; Zhaoyuan Hou; Ya Ke; Yan Li; Zhong-Ming Qian
Journal:  Autophagy       Date:  2021-02-24       Impact factor: 16.016

8.  Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Authors:  Konstantinos V Floros; Timothy L Lochmann; Bin Hu; Carles Monterrubio; Mark T Hughes; Jason D Wells; Cristina Bernadó Morales; Maninderjit S Ghotra; Carlotta Costa; Andrew J Souers; Sosipatros A Boikos; Joel D Leverson; Ming Tan; Violeta Serra; Jennifer E Koblinski; Joaquin Arribas; Aleix Prat; Laia Paré; Todd W Miller; Mikhail G Dozmorov; Hisashi Harada; Brad E Windle; Maurizio Scaltriti; Anthony C Faber
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-23       Impact factor: 11.205

9.  LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.

Authors:  Ang Gao; Tonghua Sun; Gui Ma; Jiangran Cao; Qingxia Hu; Ling Chen; Yanxin Wang; Qianying Wang; Jiafu Sun; Rui Wu; Qiao Wu; Jiaxi Zhou; Lin Liu; Junjie Hu; Jin-Tang Dong; Zhengmao Zhu
Journal:  Nat Commun       Date:  2018-10-09       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.